Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1%
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Corneal Endothelial Cell Loss
Conditions
Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
Trial Timeline
May 31, 2014 → Apr 30, 2015
NCT ID
NCT02128113About Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1%
Vehicle Ophthalmic Solution + Omaveloxolone Ophthalmic Suspension 0.5% + Omaveloxolone Ophthalmic Suspension 1% is a phase 2 stage product being developed by AbbVie for Corneal Endothelial Cell Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT02128113. Target conditions include Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02128113 | Phase 2 | Completed |
Competing Products
12 competing products in Corneal Endothelial Cell Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution | Santen Pharmaceutical | Phase 2 | 52 |
| 0.3% hypromellose | Novartis | Approved | 85 |
| Mycophenolate Mofetil 2x 1g | Roche | Approved | 85 |
| Subconjunctival aflibercept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system + placebo: 0.0% riboflavin ophthalmic solution with the KXL system | Glaukos | Phase 3 | 74 |
| Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen) | Glaukos | Phase 2 | 49 |
| lufepirsen high dose + Vehicle + lufepirsen low dose | Glaukos | Phase 2 | 49 |
| OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + Placebo | Oculis Holding AG | Phase 2 | 47 |
| DT-168 | Design Therapeutics | Phase 2 | 47 |
| KPI-012 + KPI-012 Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |
| loteprednol etabonate 0.25% ophthalmic suspension | Kala Pharmaceuticals | Approved | 77 |
| QR-504a | ProQR | Phase 1 | 25 |